Ixiaro®: A new vaccine against Japanese encephalitis

Expert Review of Vaccines

Volumn 8, Issue 11, 2009, Pages 1501-1511

  Jelinek, Tomas ^a  

^a Berlin Center for Travel and Tropical Medicine   (Germany)

Author keywords

IC51; Ixiaro ; Japanese encephalitis; Vaccine

Indexed keywords

HEPATITIS A VACCINE; IC51 VACCINE; INACTIVATED VACCINE; IXIARO; JAPANESE ENCEPHALITIS VACCINE; JESPECT; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACTIVE IMMUNIZATION; ADVERSE OUTCOME; ANGIONEUROTIC EDEMA; ANTIBODY RESPONSE; ANTIBODY TITER; BRAIN DISEASE; BRONCHITIS; CHILL; CLINICAL TRIAL; DISEASE MODEL; DIZZINESS; DRUG ANTIGENICITY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG LEGISLATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG UTILIZATION; ENCEPHALITIS; EPIDEMIC ENCEPHALITIS; FEVER; FLU LIKE SYNDROME; HAMSTER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; INJECTION SITE SWELLING; JAPANESE ENCEPHALITIS VIRUS; KIDNEY CELL CULTURE; MALAISE; MASS IMMUNIZATION; MORTALITY; MYALGIA; NAUSEA; NEUROLOGICAL COMPLICATION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVACCINATION; REVIEW; RHINOPHARYNGITIS; SEIZURE; SEROCONVERSION; SEROTYPE; SINGLE DRUG DOSE; SINUSITIS; TICK BORNE ENCEPHALITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; URTICARIA; VACCINATION; VACCINE PRODUCTION; VIRUS STRAIN; VOMITING; ASIA; AUSTRALIA; EUROPE; IMMUNOLOGY; JAPANESE ENCEPHALITIS; PHASE 3 CLINICAL TRIAL; UNITED STATES;

ASIA; AUSTRALIA; CLINICAL TRIALS, PHASE III AS TOPIC; ENCEPHALITIS, JAPANESE; EUROPE; HUMANS; JAPANESE ENCEPHALITIS VACCINES; UNITED STATES; VACCINES, INACTIVATED;

EID: 70449396890     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.112     Document Type: Review

References (86)

1. Monath TP. Flaviviruses. In: Virology. Fields BN, Knipe DM (Eds). Raven Press, NY, USA, 763-814 (1990). • Introduction to the field.
2. Chambers TJ, Hahn CS, Galler R, Rice CM. Flaviviruses genome organization, expression and repliation. Annu. Rev. Microbiol. 44, 649-688 (1990). (Pubitemid 20337531)
3. Halstead SB, Jacobsen J. Japanese encephalitis vaccines. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA, Offit P (Eds). Saunders Elsevier, MO, USA (2008). •• Authoritative overview on Japanese encephalitis (JE) vaccines.
4. Sucharit S, Surathin K, Shrestha SR. Vectors of Japanese encephalitis virus (JEV): species complexes of the vectors. Southeast Asian J. Trop. Med. Public Health 20(4), 611-621 (1989).
5. Suroso T. Studies on Japanese encephalitis vectors in Indonesia. Southeast Asian J. Trop. Med. Public Health 20(4), 627-628 (1989).
6. Oya A, Kurane I. Japanese encephalitis for a reference to international travelers. J. Travel Med. 14(4), 259-268 (2007). (Pubitemid 47041480)
7. Japanese Encephalitis vaccines: WHO position paper. Wkly Epidemiol. Rec. 81, 331-340 (2006).
8. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: Minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 18(Suppl. 2), 1-25 (2000).
9. Anonymous. Japanese encephalitis. Inactivated Japanese encephalitis virus vaccine. Wkly Epidemiol. Rec. 69(16), 113-118 (1994).
10. Anonymous. Inactivated Japanese encephalitis virus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 42(RR-1), 1-15 (1993).
11. Igarashi A. Epidemiology and control of Japanese encephalitis. World Health Stat. Q45(2-3), 299-305 (1992).
12. Umenai T, Krzysko R, Bektimirov A, Assaad A. Japanese encephalitis: current worlwide status. Bull. World Health. Organ. 63, 623-631 (1985). (Pubitemid 16214149)
13. Wong SC, Ooi MH, Abdullah AR et al. A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997-2006. Trop. Med. Int. Health 13, 52-55 (2008).
14. Kari K, Liu W, Gautama K et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med. 4, 8 (2006). (Pubitemid 43949673)
15. Bista MB, Shrestha JM. Epidemiological situation of Japanese encephalitis in Nepal. J. Nepal Med. Assoc. 44(158), 51-56 (2005).
16. Lam K, Tsang OT, Yung RW, Lau KK. Japanese encephalitis in Hong Kong. Hong Kong Med. J. 11, 182-188 (2005).
17. Hanna J, Ritchie S, Phillips D et al. Japanese encephalitis in north Queensland, Australia, 1998. Med. J. Aust. 170(11), 533-536 (1999). (Pubitemid 29261610)
18. Gingrich JB, Nisalak A, Latendresse JR et al. A longitudinal study of Japanese encephalitis in suburban Bangkok, Thailand. Southeast J. Trop. Med. Public Health 18, 558-566 (1987).
19. MacDonald WBG, Tink AR, Ouvrier RA et al. Japanese encephalitis after a two-week holiday in Bali. Med. J. Aust. 150, 334-336 (1989).
20. Rose MR, Hughes SM, Gatus BJ. A case of Japanese B encephalitis imported into the United Kingdom. J. Infect. Dis. 6, 261-265 (1983).
21. Burchard G, Caumes E, Connor BA et al. Expert opinion on vaccination of travelers against Japanese encephalitis. J. Travel Med. 16(3), 204-216 (2009). •• Current expert opinion statement on the use of the JE vaccine.
22. Buhl MR, Lindquist L. Japanese encephalitis in travelers: review of cases and seasonal risk. J. Travel Med. 16(3), 217-219 (2009). •• Very useful summary of cases in travelers.
23. Ma SP, Yoshida Y, Makino Y et al. Short report: a major genotype of Japanese encephalitis virus currently circulating in Japan. Am. J. Trop. Med. Hyg. 69(2), 151-154 (2003).
24. Solomon T. Control of Japanese encephalitis - within our grasp? N. Engl. J. Med. 355(9), 869-871 (2006). (Pubitemid 44315979)
25. Lehtinen VA, Huhtamo E, Siikamäki H, Vapalahti O. Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand. J. Clin. Virol. 43(1), 93-95 (2008).
26. Halstead SB. Arboviruses of the Pacific and Southeast Asia, In: Textbook of Pediatric Infectious Diseases. Feigin RD, Cherry JD (Eds). WB Saunders, PA, USA, 1502-1526 (1987).
27. Weaver OM. Japanese encephalitis: clinical features. Neurol. 8, 887-889 (1958).
28. Pieper SJL, Kurland LT. Sequelae of Japanese B and mumps encephalitis. Recent follow-up of patients affected in 1947-1948 epidemic on Guam. Am. J. Trop. Med. Hyg. 7, 481-490 (1958).
29. Simpson TW, Meiklejohn G. Sequelae of Japanese B encephalitis. Am. J. Trop. Med. 27, 727-731 (1947).
30. Edelman R, Schneider RJ, Chieowanich P, Pornpibul R, Voodhikul P. The effect of dengue virus infection on the clinical sequelae of Japanese encephalitis: a one year follow-up study in Thailand. Southeast J. Trop. Med. Public Health 6, 308-315 (1975).
31. Schneider RJ, Firestone MH, Edelman R, Chieowanich P, Pornpibul R. Clinical sequelae after Japanese encephalitis: a one year follow-up study in Thailand. Southeast J. Trop. Med. Public Health 5, 560-568 (1974).
32. Kedarnath N, Prasad SR, Dandawate CN, Koshy AA, George S, Ghosh SN. Isolation of Japanese encephalitis and West Nile viruses from peripheral blood of encephalitis patients. Indian J. Med. Res. 79, 1-7 (1984).
33. Han XY, Ren QW, Xu ZY, Tsai TF. Serum and cerebrospinal fluid immunoglobulins M, A and G in Japanese encephalitis. J. Clin. Microbiol. 26, 976-978 (1988).
34. Tauber E, Kollaritsch H, Korinek M et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, Phase III, randomised controlled trial. Lancet 370(9602), 1847-1853 (2007). •• Important Phase III study.
35. Oya A. Japanese encephalitis vaccine. Acta Paediatr. Jpn 30(2), 175-184 (1988).
36. Tsarev SA, Sanders ML, Vaughn DW et al. Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus . Vaccine 18(Suppl. 2), 36-43 (2000).
37. Chen WR, Tesh RB, Rico-Hesse R. Genetic variation of Japanese encephalitis virus in nature. J. Gen. Virol. 71, 2915-2922 (1990).
38. Stephenson JR. Flavivirus vaccines. Vaccine 6, 471-480 (1988).
39. Schioler KL, Samuel M, Wai KL. Vaccines for preventing Japanese encephalitis. Cochrane Database Syst. Rev. 3, 1-44 (2007).
40. Jelinek T. Japanese encephalitis vaccine in travelers. Expert Rev. Vaccines 7(5), 689-693 (2008). • Opinion paper on the use of JE vaccine and overview of current products.
41. Hoke C, Nisalak A, Sangawhipa N et al. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319, 608-614 (1988). (Pubitemid 18209710)
42. Poland J, Cropp C, Craven R, Monath T. Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants. J. Infect. Dis. 161, 878-882 (1990). (Pubitemid 20148317)
43. Sanchez J, Hoke C, McCowan J. Further experience with Japanese encephalitis vaccine. Lancet 335, 972-973 (1990). (Pubitemid 20135000)
44. Anonymous. Japanese encephalitis vaccine and adverse effects among travelers. Can. Dis. Wkly Rep. 17, 173-177 (1991).
45. Berg SW, Mitchell BS, Hanson RK et al. Systemic reactions in U.S. Marine Corps personnel who received Japanese encephalitis vaccine. Clin. Infect. Dis. 24, 265-266 (1997).
46. Ohtaki E, Murakami Y, Komori H, Yamashita Y, Matsuishi T. Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination. Pediatr. Neurol. 8(2), 137-139 (1992).
47. Andersen MM, Ronne T. Side-effects with Japanese encephalitis vaccine [letter]. Lancet 337(8748), 1044 (1991).
48. Ruff TA, Eisen D, Fuller A, Kass R. Adverse reactions to Japanese encephalitis vaccine [letter]. Lancet 338(8771), 881-882 (1991).
49. Nothdurft HD, Jelinek T, Marschang A, Maiwald H, Kapaun A, Löscher T. Adverse reactions to Japanese encephalitis vaccine in German travelers. J. Infect. 32, 119-122 (1996). (Pubitemid 26131692)
50. Beasley DW, Lewthwaite P, Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opin. Biol. Ther. 8(1), 95-106 (2008). (Pubitemid 351233725)
51. Luo D, Yin H, Xili L, Song J, Wang Z. The efficacy of Japanese encephalitis vaccine in Henan, China: a case-control study. Southeast Asian J. Trop. Med. Public Health 25(4), 643-646 (1994).
52. Liu ZL, Hennessy S, Strom BL et al. Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14- 12): results of a randomized trial with 26,239 subjects. J. Infect. Dis. 176(5), 1366-1369 (1997). (Pubitemid 27461005)
53. Hennessy S, Zehngle L, Tsai T et al. Effectiveness of live-attenuated japanese encephalitis vaccine (SA 14-14-12): a case control study. Lancet 347, 1583-1586 (1996). (Pubitemid 26170875)
54. Bista MB, Banerjee MK, Shin SH et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case control study. Lancet 358(9284), 791-795 (2001).
55. Ohrr H, Tandan JB, Sohn YM et al. Effect of single dose of SA 14-14-12 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366(9494), 1375-1378 (2005). (Pubitemid 41443404)
56. Guirakhoo F, Zhang ZX, Chambers TJ et al. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257, 363-372 (1999). (Pubitemid 29393404)
57. Monath TP, Soike K, Levenbook I et al. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-12) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17, 1869-1882 (1999).
58. Monath TP, Guirakhoo F, Nichols R et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J. Infect. Dis. 188, 1213-1230 (2003). (Pubitemid 37338987)
59. Lyons A, Kanesa-thasan N, Kuschner RA et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25(17), 3445-3453 (2007). (Pubitemid 46527985)
60. Srivastava AK, Putnak JR, Lee SH et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19(31), 4557-4565 (2001).
61. Ni H, Burns NJ, Chang GJ et al. Comparison of nucleotide and deduced amino acid sequence of the 5′ non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J. Gen. Virol. 75( Pt 6), 1505-1510 (1994). (Pubitemid 24174071)
62. Hombach J, Solomon T, Kurane I et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23(45), 5205-5211 (2005). (Pubitemid 41443426)
63. Schuller E, Jilma B, Voicu V et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51: six and 12 month results of a multicenter follow-up Phase 3 study. Vaccine 26(34), 4382-4386 (2008). • Long-term data on IC51 immunogenicity.
64. Kollaritsch H, Paulke-Korinek M, Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opin. Biol. Ther. 9(7), 921-931 (2009).
65. Schuller E, Klade CS, Wolfl G et al. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 27(15), 2188-2193 (2009). • Dose-finding study.
66. Dubischar-Kastner K, Eder S, Kaltenboeck A, Klade C, Schuller E, Wölfl C. Long term immunity following vaccination with the inactivated Japanese encephalitis vaccine Ixiaro® and neutralizing antibody response to a booster dose. Presented at: 11th Conference of the International Society of Travel Medicine. Budapest, Hungary, 24-28 May 2009 (Poster presentation). • Long-term data on IC51 immunogenicity.
67. Kaltenböck A, Dubischar-Kastner K, Eder G et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX® 1440 in healthy subjects: a single-blind, randomized, controlled Phase 3 study. Vaccine 27(33), 4483-4489 (2009). • Data on concomitant vaccination with hepatitis A vaccine.
68. Schuller E, Klade CS, Heinz FX et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 26(48), 6151-6156 (2008). • Data on cross-reactivity with related flaviviruses.
69. Schuller KT, Klade C, Kaltenboeck A et al. First clinical trial of a vero cell derived, inactivated Japanese encephalitis (JE) vaccine IC51 in pediatric population. Presented at: ASTMH Annual Meeting. New Orleans, USA, 7-11 December 2008 (Abstract 835).
70. Hammon WM, Sather GE. Passive immunity for arbovirus infection. I. Artificially induced prophylaxis in man and mouse for Japanese (B) encephalitis. Am. J. Trop. Med. Hyg. 22(4), 524-534 (1973).
71. Duggan ST, Plosker GL. Japanese encephalitis vaccine (inactivated, adsorbed) (IXIARO). Drugs 69(1), 115-122 (2009). • First pediatric data.
72. Dubischar-Kastner K, Kaltenboeck A, Schuller E et al. Six months safety of a vero-cell derived Japanese Encephalitis vaccine, IXIARO, IC51, across Phase 3 trials and in a long term follow up cohort. Presented at: ASTMH Annual Meeting. New Orleans, USA, 7-11 December 2008 (Abstract 836).
73. Tauber E, Kollaritsch H, von Sonnenburg F et al. Randomized, double-blind, placebocontrolled Phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J. Infect. Dis. 198(4), 493-499 (2008).
74. Plesner AM. Allergic reactions to Japanese encephalitis vaccine. Immunol. Allergy Clin. North Am. 23(4), 665-697 (2003). •• Comprehensive review of neurological and allergic reactions to Japanese encephalitis vaccines.
75. Ohtaki E, Matsuishi T, Hirano Y, Maekawa K. Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains). J. Neurol. Neurosurg. Psychiatry 59(3), 316-317 (1995).
76. Nazareth B, Levin J, Johnson H, Begg N. Systemic allergic reactions to Japanese encephalitis vaccines. Vaccine 12(7), 666 (1994). (Pubitemid 24153536)
77. Hanna J, Ritchie S, Phillips D et al. Japanese encephalitis in north Queensland, Australia, 1998. Med. J. Aust. 170(11), 533-536 (1999). (Pubitemid 29261610)
78. Shlim DR, Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin. Infect. Dis. 35(2), 183-188 (2002). (Pubitemid 34753904)
79. Steffen R, Connor BA. Vaccines in travel health: from risk assessment to priorities. J. Travel Med. 12(1), 26-35 (2005). (Pubitemid 40216108)
80. Wittesjo B, Eitrem R, Niklasson B et al. Japanese encephalitis after a 10-day holiday in Bali. Lancet 345(8953), 856-857 (1995).
81. Caramello P, Canta F, Balbiano R et al. A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader? J. Travel Med. 14(5), 346-348 (2007). (Pubitemid 47460248)
82. WHO. Japanese encephalitis www.who.int/vaccine-research/ diseases/vector/en/index1.html • Current WHO data.
83. WHO. Report of the Bi-Regional Meeting on Japanese Encephalitis, 2005 www.wpro.who.int/NR/rdonlyres/ A62D4A75-0C28-4093-95CF- 555CE379C469/0/MTGRPT- BiregionalJE2005.pdf
84. Yaïch M, Jacobson J. Satellite symposium on Japanese encephalitis and dengue vaccine research. Proceedings of the Seventh Global Vaccine Research Forum And Parallel Satellite Symposia. 3-6 December 2006, Bangkok, Thailand http://whqlibdoc.who.int/hq/2007/ WHO-IVB-07.10-eng.pdf
85. ClinicalTrails.gov http://clinicaltrials.gov/ct2/ results?term=IC51
86. Intercell. Intercell for Vaccperts www.intercell.com/main/forvaccperts/ products/japanese-encephalitis-vaccine/ •• Useful source of information on IC51.